UPDATE: The Avastin Argument

Premium

UPDATE: An FDA advisory panel has once again voted to remove the breast cancer indication from Avastin's label, unconvinced by evidence presented by Roche that claims certain breast cancer patients respond very well to the drug. Despite FDA's decision, Roche subsidiary Genentech says it will move forward with plans to study a certain group of breast cancer patients with high levels of VEGF-A that the company calls "super responders," as they respond to Avastin very well.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.